Collectively, these findings indicate that TTPAL expression may serve as a novel biomarker for stratifying patients likely to benefit from cholesterol biosynthesis-targeted therapeutic strategies in ESCC. The gene discussed is TTPAL; the disease is esophageal squamous cell carcinoma.